Silo Pharma Secures Australian Patent For SPC-15 PTSD Treatment; Reinforces Intranasal PTSD Therapy Development

Silo Pharma, Inc. announced that IP Australia has granted patent number 2020271839 to Columbia University for an invention related to stress prevention using serotonin 4 receptor agonists. The patent is exclusively licensed to Silo, further strengthening the company’s intellectual property portfolio.

“This patent further strengthens our global IP portfolio for SPC-15, protecting its novel approach to preventing stress-induced disorders and enhancing stress resilience,” said Silo CEO Eric Weisblum. “The claims further strengthen and support our plans for clinical trial development of SPC-15 as an innovative therapeutic for PTSD.”

The newly granted patent provides expanded protection for SPC-15, Silo’s lead intranasal therapy for post-traumatic stress disorder (PTSD), which was originally developed by Columbia University. SPC-15 targets the serotonin 5-HT4 receptor and is designed to address psychiatric conditions linked to stress, including PTSD and anxiety.

Silo Pharma holds exclusive global rights to develop and commercialize SPC-15 and is collaborating with Columbia University on preclinical research. With potential eligibility for the FDA’s streamlined 505(b)(2) regulatory pathway, SPC-15 represents a promising candidate to accelerate development and approval timelines in addressing critical unmet needs in mental health.